US Stock MarketDetailed Quotes

STAB Statera Biopharma

Watchlist
  • 0.000600
  • 0.0000000.00%
Close Mar 28 16:00 ET
42.85KMarket Cap0.00P/E (TTM)

About Statera Biopharma Company

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

Company Profile

SymbolSTAB
Company NameStatera Biopharma
Listing Date07/21/2006
Issue Price6.00
Founded2003
CEOMr. Michael K. Handley
MarketPink Market
Employees46
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address4333 Corbett Drive,Suite 1082
CityFort Collins
ProvinceColorado
CountryUnited States of America
Zip Code80525
Phone1-888-613-8802

Company Executives

  • Name
  • Position
  • Salary
  • Michael K. Handley
  • Chairman of the Board, President and Chief Executive Officer
  • 2.87M
  • Dr. Robert W. Buckheit
  • Chief Technology Officer
  • --
  • Christopher Zosh
  • Interim Principal Financial Officer, Interim Principal Accounting Officer and Executive Vice President of Finance
  • 103.49K
  • Dr. Andrei Gudkov, D.Sc.,PhD
  • Vice President of Global Development
  • 66.14K
  • John A. Kallassy
  • Independent Director
  • --
  • Dr. Uday Saxena
  • Independent Director
  • --
  • Selby Blake Hawley
  • Independent Director
  • --
  • Dr. Satish Chandran
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg